{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T13:43:01Z","timestamp":1649079781146},"reference-count":22,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2022.2493","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T16:11:22Z","timestamp":1644423082000},"source":"Crossref","is-referenced-by-count":1,"title":["Cervical dissecting extravasation of oxaliplatin: A case report"],"prefix":"10.3892","volume":"16","author":[{"given":"Jorge","family":"Hernando","sequence":"first","affiliation":[{"name":"Gastrointestinal and Endocrine Tumors Unit, Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Autonomous University of Barcelona, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Riera\u2011Arnau","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Service, Department of Pharmacovigilance and Pharmacoepidemiology, Vall d'Hebron University Hospital, Autonomous University of Barcelona, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Roca","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Endocrine Tumors Unit, Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Autonomous University of Barcelona, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Garcia","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Endocrine Tumors Unit, Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Autonomous University of Barcelona, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[{"name":"Gastrointestinal and Endocrine Tumors Unit, Department of Medical Oncology, Vall d'Hebron Institute of Oncology, Autonomous University of Barcelona, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"key20220302120055_b1-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1039\/d0mt00194e","article-title":"Proteomic analysis of cisplatin- and oxaliplatin-induced phosphorylation in proteins bound to Pt-DNA adducts","volume":"12","author":"Yuan","year":"2020","journal-title":"Metallomics"},{"key":"key20220302120055_b2-MCO-16-3-02493"},{"key":"key20220302120055_b3-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1634\/stemcells.2006-CSC2","article-title":"The molecular perspective: Cisplatin","volume":"11","author":"Goodsell","year":"2006","journal-title":"Oncologist"},{"key":"key20220302120055_b4-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1007\/s12094-018-1854-z","article-title":"Management of extravasation of oxaliplatin by mimicking its biotransformation","volume":"20","author":"Bahadori","year":"2018","journal-title":"Clin Transl Oncol"},{"key":"key20220302120055_b5-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1159\/000027218","article-title":"Extravasation of oxaliplatin (Eloxatin((R)))-clinical course","volume":"23","author":"Baur","year":"2000","journal-title":"Onkologi"},{"key":"key20220302120055_b6-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"vii167","DOI":"10.1093\/annonc\/mds294","article-title":"Management of chemotherapy extravasation: ESMO-EONS clinical practice guidelines","volume":"23 (Suppl 7)","author":"P\u00e9rez Fidalgo","year":"2012","journal-title":"Ann Oncol"},{"key":"key20220302120055_b7-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s12094-009-0324-z","article-title":"Extravasation of oxaliplatin: An infrequent and irritant toxicity","volume":"11","author":"Pericay","year":"2009","journal-title":"Clin Transl Oncol"},{"key":"key20220302120055_b8-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1188\/06\/ONF.1143-1150","article-title":"Vesicant extravasation part II: Evidence-based management and continuing controversies","volume":"33","author":"Wickham","year":"2006","journal-title":"Oncol Nurs Forum"},{"key":"key20220302120055_b9-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"87","DOI":"10.5306\/wjco.v7.i1.87","article-title":"Overview, prevention and management of chemotherapy extravasation","volume":"7","author":"Kreidieh","year":"2016","journal-title":"World J Clin Oncol"},{"key":"key20220302120055_b10-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.ejso.2011.06.016","article-title":"Totally implantable venous access port systems and risk factors for complications: A one-year prospective study in a cancer centre","volume":"37","author":"Narducci","year":"2011","journal-title":"Eur J Surg Oncol"},{"issue":"bcr2014204360","key":"key20220302120055_b11-MCO-16-3-02493","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-204360","article-title":"A midline for oxaliplatin infusion: The myth of safety devices","volume":"2014","author":"Masters","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"V07140390","key":"key20220302120055_b12-MCO-16-3-02493","article-title":"Reversible tissue damage after paravasal infusion of oxaliplatin","volume":"177","author":"Boesen","year":"2015","journal-title":"Ugeskr Laeger"},{"key":"key20220302120055_b13-MCO-16-3-02493","first-page":"546","article-title":"Extravasation of oxaliplatin into the mediastinum: A case report and review of the literature","volume":"10","author":"Leon-Ferre","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"key20220302120055_b14-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ejso.2014.11.042","article-title":"Port-a-Cath extravasation of vesicant cytotoxics: Surgical options for a rare complication of cancer chemotherapy","volume":"41","author":"Haslik","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"key20220302120055_b15-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5301\/jva.5000316","article-title":"Chemotherapy drug extravasation in totally implantable venous access port systems: How effective is early surgical lavage?","volume":"16","author":"Aza\u00efs","year":"2015","journal-title":"J Vasc Access"},{"issue":"207084","key":"key20220302120055_b16-MCO-16-3-02493","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/207084","article-title":"Hypersensitivity reactions associated with platinum antineoplastic agents: A systematic review","volume":"2010","author":"Makrilia","year":"2010","journal-title":"Met Based Drugs"},{"key":"key20220302120055_b17-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1188\/04.CJON.251-256","article-title":"Oxaliplatin: Practical guidelines for administration","volume":"8","author":"Sorich","year":"2004","journal-title":"Clin J Oncol Nurs"},{"key":"key20220302120055_b18-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1517\/14740338.2.6.597","article-title":"Toxicities of the platinum antineoplastic agents","volume":"2","author":"Markman","year":"2003","journal-title":"Expert Opin Drug Saf"},{"key":"key20220302120055_b19-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1191\/1078155205jp165oa","article-title":"Management of extravasation of oxaliplatin","volume":"11","author":"de Lemos","year":"2005","journal-title":"J Oncol Pharm Pract"},{"key":"key20220302120055_b20-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"4068","DOI":"10.1200\/JCO.2003.99.095","article-title":"Extravasations of oxaliplatin","volume":"21","author":"Kretzschmar","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20220302120055_b21-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1093\/annonc\/mdg252","article-title":"A case report of oxaliplatin extravasation","volume":"14","author":"Foo","year":"2003","journal-title":"Ann Oncol"},{"key":"key20220302120055_b22-MCO-16-3-02493","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.farma.2011.01.002","article-title":"Update in the management of extravasations of cytocytostatic agent","volume":"36","author":"Conde-Est\u00e9vez","year":"2012","journal-title":"Farm Hosp"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T10:01:02Z","timestamp":1646215262000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2022.2493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,1,12]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2022.2493","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,12]]},"article-number":"60"}}